From: Immunotherapy for Merkel cell carcinoma: a turning point in patient care
Anti-neoplastic agent(s)
Median PFS, months (95% CI)
PFS rate at 12Â months, % (95% CI)
Reference
Avelumab (N = 88)
2.7 (1.4–6.9)
30 (21–41)
[39]
Cowey 2017 (n = 20)
2.1 (1.0–3.2)
0
[42]
Becker 2016 (n = 34)
3.0 (2.6–3.1)
[43]
Iyer 2016 (n = 30)
2.0 (NA [range: 0.4–11.6])
0*
[14]